UnitedHealthcare Community Plan

Hemlibra - Nebraska
Prior Authorization Request Form

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826.**
This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information (if any):		

Is the requested medication: □ New or □ Continuation of Therapy? If continuation, list start date: _____

Is this patient currently hospitalized? □ Yes □ No If recently discharged, list discharge date: _____

Section B - Provider Information

First Name:		Last Name:		M.D./D.O.
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information

Medication:	**Strength:**
Directions for use:	**Quantity:**
Diagnosis (Please be specific & provide as much information as possible)**:**	**ICD-10 CODE:**

Is this member pregnant? □ Yes □ No If yes, what is this member's due date? _____

Section D – Previous Medication Trials

Medication Name	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs: Please refer to the patient's PDL for a list of preferred alternatives

UnitedHealthcare Community Plan

Hemlibra - Nebraska
Prior Authorization Request Form

Member First name:	Member Last name:	Member DOB:

Clinical and Drug Specific Information	
ALL REQUESTS	
□ **Yes** □ **No**	**Does the patient have a diagnosis of one of the following?** *(If yes, check which applies)* □ Mild hemophilia A □ Moderate hemophilia A □ Severe hemophilia A
□ **Yes** □ **No**	**Has the patient developed factor VIII inhibitors?**
	List endogenous factor VIII level: _____
□ **Yes** □ **No**	**Is Hemlibra prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)?**
WITHOUT INHIBITORS	
□ **Yes** □ **No**	**Does the physician attest the patient is not to receive extended half-life factor VIII replacement products (e.g., Eloctate, Adynovate, Afstyla, Jivi) for the treatment of breakthrough bleeding episodes?**
□ **Yes** □ **No**	**Is there submission of medical records (e.g. chart notes, laboratory values) documenting a failure to meet clinical goals (e.g., continuation of spontaneous bleeds, inability to achieve appropriate trough level, previous history of inhibitors) after a trial of prophylactic factor VIII replacement products?** *(If yes, attach medical records and complete Section D above)*
CONTINUATION OF THERAPY	
□ **Yes** □ **No**	**Does the patient have a documented positive clinical response to Hemlibra therapy?** *If yes, list positive response:*

Provider Signature: _____ **Date:** _____